Assenagon Asset Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $32.4M | Buy |
3,620,637
+3,606,566
| +25,631% | +$32.3M | 0.05% | 263 |
|
|
2025
Q1 | $106K | Hold |
14,071
| – | – | ﹤0.01% | 1111 |
|
|
2024
Q4 | $106K | Hold |
14,071
| – | – | ﹤0.01% | 1270 |
|
|
2024
Q3 | $107K | Sell |
14,071
-50,836
| -78% | -$386K | ﹤0.01% | 1304 |
|
|
2024
Q2 | $401K | Sell |
64,907
-321,978
| -83% | -$1.99M | ﹤0.01% | 1229 |
|
|
2024
Q1 | $1.97M | Sell |
386,885
-142,534
| -27% | -$724K | ﹤0.01% | 881 |
|
|
2023
Q4 | $3.17M | Sell |
529,419
-580,485
| -52% | -$3.48M | 0.01% | 740 |
|
|
2023
Q3 | $7.86M | Sell |
1,109,904
-4,223,010
| -79% | -$29.9M | 0.02% | 421 |
|
|
2023
Q2 | $37.5M | Buy |
5,332,914
+365,077
| +7% | +$2.57M | 0.13% | 121 |
|
|
2023
Q1 | $41.4M | Buy |
4,967,837
+2,377,445
| +92% | +$19.8M | 0.15% | 116 |
|
|
2022
Q4 | $29.7M | Sell |
2,590,392
-25,765
| -1% | -$296K | 0.11% | 173 |
|
|
2022
Q3 | $33M | Sell |
2,616,157
-561,714
| -18% | -$7.08M | 0.13% | 141 |
|
|
2022
Q2 | $33.6M | Buy |
3,177,871
+3,107,027
| +4,386% | +$32.9M | 0.12% | 142 |
|
|
2022
Q1 | $1.15M | Buy |
70,844
+57,608
| +435% | +$937K | ﹤0.01% | 987 |
|
|
2021
Q4 | $183K | Sell |
13,236
-53,891
| -80% | -$745K | ﹤0.01% | 1335 |
|
|
2021
Q3 | $965K | Sell |
67,127
-687,905
| -91% | -$9.89M | ﹤0.01% | 873 |
|
|
2021
Q2 | $11.9M | Buy |
755,032
+710,563
| +1,598% | +$11.2M | 0.04% | 277 |
|
|
2021
Q1 | $452K | Buy |
+44,469
| New | +$452K | ﹤0.01% | 1003 |
|
|
2020
Q3 | – | Sell |
-303,400
| Closed | -$1.45M | – | 1090 |
|
|
2020
Q2 | $1.45M | Buy |
+303,400
| New | +$1.45M | 0.01% | 668 |
|
|
2020
Q1 | – | Sell |
-74,744
| Closed | -$258K | – | 758 |
|
|
2019
Q4 | $258K | Buy |
+74,744
| New | +$258K | ﹤0.01% | 673 |
|